- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MRK
Recent news which mentions MRK
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
February 12, 2024
From Benzinga
2 Value Stocks With Monster Yields
February 12, 2024
From Motley Fool
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
February 09, 2024
From Benzinga
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
February 08, 2024
From Motley Fool
From Benzinga
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
From InvestorPlace
Elanco Animal Health To Offload Aqua Business For $1.3B, Plans To Lower Debt Burden
February 05, 2024
From Benzinga
7 Mutual Funds That Will Outperform in Any Market
February 03, 2024
From InvestorPlace
3 Pharma Stocks to Sell in February Before They Crash and Burn
February 02, 2024
From InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
From Benzinga
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
February 02, 2024
From Benzinga
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
From Benzinga
Stocks Recoup Post-Fed Losses As Traders Challenge Powell, Regional Banks Crack, Gold Rises: What's Driving Markets Thursday?
February 01, 2024
From Benzinga
Merck Posts Surprise Quarterly Profit Against An Expected Loss, Oncology And Vaccines Drive Growth
February 01, 2024
From Benzinga
Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year
February 01, 2024
From Benzinga
Earnings Scheduled For February 1, 2024
February 01, 2024
From Benzinga
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
From Benzinga
Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings
January 29, 2024
From Benzinga
From Benzinga
Hope for Kidney Cancer Patients, Merck's Keytruda Cuts Risk Of Death By 38% Following Surgery
January 29, 2024
From Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
January 28, 2024
From Motley Fool
Merck's Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
January 26, 2024
From Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
January 26, 2024
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.